Pulmicort Turbuhaler, 100 μg/inhalation dose, inhalation powder
Pulmicort Turbuhaler, 200 μg/inhalation dose, inhalation powder
Budesonide
Budesonide, the active substance of Pulmicort Turbuhaler, belongs to a group of medicines called glucocorticosteroids. Medicines in this group have strong local anti-inflammatory effects. Pulmicort Turbuhaler is used in:
Before starting treatment with Pulmicort Turbuhaler, the patient should inform their doctor if:
The patient should inform their doctor about any planned stressful situations (e.g., exams) or planned surgeries. The doctor may then consider increasing the dose of oral glucocorticosteroids. If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
The medicine is intended for use in the treatment of bronchial asthma in children aged 6 and older. Regular monitoring of growth in children and adolescents taking glucocorticosteroids is recommended, regardless of the route of administration.
The patient should inform their doctor about any past or present liver function disorders.
The patient should inform their doctor about any worrying reactions that occurred after taking other medicines. The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those that are available without a prescription and herbal preparations. Pulmicort Turbuhaler may affect the way some medicines work, and some medicines may affect the way Pulmicort Turbuhaler works. In particular, the patient should inform their doctor if they are taking:
Pregnancy If the patient is pregnant, thinks they may be pregnant, or plans to have a child, they should consult their doctor before using this medicine. If a woman treated with Pulmicort Turbuhaler becomes pregnant, she should inform her doctor as soon as possible. Breastfeeding Before using the medicine, the patient should consult their doctor.
Pulmicort Turbuhaler does not affect the ability to drive or use machines.
The dosage of Pulmicort Turbuhaler is individual. The following are general recommendations for determining the total initial dose, the maximum total dose of Pulmicort Turbuhaler, depending on previous asthma treatment and the patient's age. As with other inhaled medicines, a paradoxical bronchospasm may occur immediately after using Pulmicort Turbuhaler. If a severe reaction occurs, the patient should see their doctor immediately. The patient should also see their doctor if the symptoms of the disease do not improve despite systematic use of the recommended doses.
The lowest effective maintenance dose is recommended. Due to the very small amount of inhaled powder, the patient may not feel the taste of the medicine after inhalation. Improvement in clinical condition after administration of one dose of Pulmicort Turbuhaler can be expected after a few hours of inhalation. The full therapeutic effect is achieved after several weeks of treatment. Pulmicort Turbuhaler is intended for long-term treatment and does not provide quick relief of acute asthma attacks. When changing treatment from oral glucocorticosteroids to inhaled medicines, the patient should be in a relatively stable condition. For 10 days, it is recommended to use high doses of Pulmicort Turbuhaler in combination with the previously used oral glucocorticosteroid. Then, the dose of the oral glucocorticosteroid should be gradually reduced. Often, the use of oral glucocorticosteroids can be completely stopped.
In the case of patients with COPD who are taking oral glucocorticosteroids and are prescribed Pulmicort Turbuhaler, the same recommendations should be followed as for "Bronchial asthma". In the event of worsening COPD symptoms, the patient should contact their attending physician, who will recommend appropriate treatment. If there is no noticeable improvement after using short-acting bronchodilators or if they need to be used more frequently than usual, the patient should see their doctor.
Before the firstuse of a newPulmicort Turbuhaler inhaler, it should be prepared for use as follows:
To perform an inhalation, follow the instructions below each time. The Turbuhaler is a multi-dose inhaler for administering the medicine.
When inhaling through the Turbuhaler, the powder is released into the lungs. Therefore, it is very important to take a full, deep breath through the mouthpiece. The patient should follow the instructions below.
Never EXHALEthrough the mouthpiece. After taking the medicine, the patient should always screw the cap on tightly. Due to the very small amount of powdered medicine, the patient may not feel the taste of the medicine after inhalation. However, the patient can be sure that the prescribed dose has been taken if they follow the instructions above.
The outer part of the mouthpiece should be cleaned regularly (once a week) with a dry cloth.
Dose indicator When the red mark first appears in the control window, it means that there are about 20 doses left in the device (Figure 1). When the red stripe reaches the bottom of the control window (Figure 2), it means that the inhaler can no longer be used. The dose of medicine released from the inhaler may then be too small. When shaking the inhaler, a characteristic sound of the desiccant flowing can be heard.
Figure 1 Figure 2 If the patient feels that the effect of Pulmicort Turbuhaler is too strong or too weak, they should consult their doctor.
It is important for the patient to use the medicine as directed by the doctor. The patient should not increase or decrease the dose of the medicine without consulting their doctor. If the patient takes more than the recommended dose of the medicine, they should see their doctor immediately.
Pulmicort Turbuhaler in the form of inhalation powder should be taken as directed by the doctor and only the prescribed number of doses should be taken. The patient should not take a double dose to make up for a missed dose. If the patient has any further doubts about using this medicine, they should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
if the patient experiences any of the following symptoms:severe allergic reactions, e.g., swelling of the face, especially around the mouth (tongue and/or throat) and/or difficulty swallowing or hives occurring at the same time as difficulty breathing (angioedema), bronchospasm, and/or sudden weakness (fainting).
The patient should tell their doctor if they experience any of the following symptoms, which may be signs of a lung infection:
Systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone density, cataracts, glaucoma, and less frequently, psychiatric or behavioral problems, including psychomotor hyperactivity, sleep disturbances, anxiety, depression, or aggression (especially in children). If the patient experiences any of these side effects, they should contact their doctor or go to the nearest hospital immediately.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
Store at a temperature not exceeding 30°C. The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the packaging after the "EXP" date. The expiry date refers to the last day of the month stated. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of Pulmicort Turbuhaler is budesonide. One dose contains 100 micrograms (μg) or 200 micrograms (μg) of budesonide.
A dose counter with a mouthpiece and a protective cap in a cardboard box. Pulmicort Turbuhaler 100 μg contains 200 doses. Pulmicort Turbuhaler 200 μg contains 100 doses. Each inhaler is also labeled with: 200 DOSES BUDESONIDE 100 μg/DOSE LOT/CH.-B/LOTE ZM 1234 EXP/VERW.BIS/CAD MM-YYYY or 100 DOSES BUDESONIDE 200 μg/DOSE LOT/CH.-B/LOTE ZM 1234 EXP/VERW.BIS/CAD MM-YYYY
Marketing authorization holder: AstraZeneca AB S-151 85 Sodertalje Sweden Manufacturer: AstraZeneca AB Forskargatan 18 151 36 Södertälje Sweden For more information, the patient should contact the representative of the marketing authorization holder: AstraZeneca Pharma Poland Sp. z o.o. ul. Postępu 14 02-676 Warsaw tel: +48 22 245 73 00 fax: +48 22 485 30 07 Date of last revision of the leaflet:November 2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.